Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EU-COVAT-1 AGED (4th dose COVID-19 booster in adults ≥75 years)
2021-004526-29Phase 2Completed
- Sponsor
- University of Cologne
- Start
- Sep 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of elasomeran in coronavirus disease 2019 (COVID-19), sponsored by University of Cologne. Primary endpoint: Rate of 2-fold antibody titre increase 14 days after the 4th vaccination dose. Started Sep 2021; status: completed.
02
Drugs
elasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-004526-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004526-29.